Volume | 278,299 |
|
|||||
News | - | ||||||
Day High | 8.07 | Low High |
|||||
Day Low | 7.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Avidity Biosciences Inc | RNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.78 | 7.57 | 8.07 | 7.72 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,379 | 278,299 | $ 7.83 | $ 2,178,859 | - | 4.825 - 25.74 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:23:33 | 50 | $ 7.97 | USD |
Avidity Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
590.59M | 74.10M | - | 9.22M | -174M | -2.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Avidity Biosciences News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.19 | 8.68 | 7.19 | 7.86 | 2,806,584 | 0.77 | 10.71% |
1 Month | 5.80 | 8.68 | 5.15 | 7.12 | 2,152,241 | 2.16 | 37.24% |
3 Months | 7.30 | 8.68 | 4.825 | 6.71 | 1,255,892 | 0.66 | 9.04% |
6 Months | 11.28 | 12.71 | 4.825 | 8.33 | 1,074,020 | -3.32 | -29.43% |
1 Year | 11.21 | 25.74 | 4.825 | 13.89 | 1,375,801 | -3.25 | -28.99% |
3 Years | 32.52 | 35.87 | 4.825 | 15.79 | 683,730 | -24.56 | -75.52% |
5 Years | 26.50 | 37.46 | 4.825 | 16.46 | 616,835 | -18.54 | -69.96% |
Avidity Biosciences Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease. |